HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals : Post Hoc Analysis of Japanese Patients (MELODY Study)

この資料はクリエイティブ・コモンズ・ライセンスの下で公開されています。

フルテキスト
40744_2015_23_MOESM1_ESM.pdfSupporting Information230.01 kBPDF見る/開く
134_art_10.1007_s40744-015-0023-x.pdf551.01 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/62851

タイトル: Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals : Post Hoc Analysis of Japanese Patients (MELODY Study)
著者: Koike, Takao 著作を一覧する
Harigai, Masayoshi 著作を一覧する
Ishiguro, Naoki 著作を一覧する
Inokuma, Shigeko 著作を一覧する
Takei, Syuji 著作を一覧する
Takeuchi, Tsutomu 著作を一覧する
Yamanaka, Hisashi 著作を一覧する
Takasaki, Yoshinari 著作を一覧する
Mimori, Tsuneyo 著作を一覧する
Hisamatsu, Katsutoshi 著作を一覧する
Komatsu, Shuichi 著作を一覧する
Tanaka, Yoshiya 著作を一覧する
キーワード: Adalimumab
Doses
Effectiveness
Methotrexate
Rheumatoid arthritis
Safety
発行日: 2016年 6月
出版者: Springer Healthcare
誌名: Rheumatology and Therapy
巻: 3
号: 1
開始ページ: 129
終了ページ: 141
出版社 DOI: 10.1007/s40744-015-0023-x
抄録: Introduction: There is insufficient evidence regarding the appropriate dose of methotrexate (MTX) required to achieve specific treatment goals in patients with rheumatoid arthritis (RA) receiving biologic drugs in Japan. The present study aimed to assess the dose-response effect of MTX in combination with adalimumab (ADA) to achieve low disease activity (LDA) and/or remission at 24 weeks in RA patients. Methods: This analysis used data of the ADA all-case survey in Japan (n = 7740), and 5494 patients who received ADA and MTX were classified into five groups by weighted average MTX dose (>0-<4, 4-<6, 6-<8, 8-< 10, and ≥10 mg/week). Of the 5494 patients, 3097 with baseline 28-joint disease activity score based on erythrocyte sedimentation rate >3.2 were analyzed for effectiveness by MTX dose. Results: In biologic-naive patients (n = 1996/3097), LDA/remission rates increased with MTX up to 6-<8 mg/week and then plateaued at higher doses (LDA, p = 0.0440; remission, p = 0.0422). In biologic-exposed patients (n = 1101/3097), LDA/remission rates increased with MTX dose (LDA, p = 0.0009; remission p = 0.0143). The incidences of serious adverse drug reactions (ADRs) and serious infections did not differ by MTX dose, but total ADRs and infections were significantly higher (p < 0.05) with increased MTX doses. Conclusion: The appropriate MTX doses in combination with ADA to achieve LDA and/or remission at week 24 were different between biologic-naive and biologic-exposed patients with RA, suggesting that 8 mg/week of MTX would be enough for biologic-naive patients.
資料タイプ: article
URI: http://hdl.handle.net/2115/62851
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 小池 隆夫

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学